Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 8.99 -2.50% -0.23
SYRS closed down 3.86 percent on Friday, March 22, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Up Up
See historical SYRS trend table...

Date Alert Name Type % Chg
Mar 22 NR7 Range Contraction -2.49%
Mar 22 Upper Bollinger Band Walk Strength -2.49%
Mar 22 Inside Day Range Contraction -2.49%
Mar 22 Wide Bands Range Expansion -2.49%
Mar 22 Overbought Stochastic Strength -2.49%
Mar 21 200 DMA Support Bullish -6.26%
Mar 21 New Uptrend Bullish -6.26%
Mar 21 Pocket Pivot Bullish Swing Setup -6.26%
Mar 21 Upper Bollinger Band Walk Strength -6.26%
Mar 21 Wide Bands Range Expansion -6.26%

Older signals for SYRS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Diseases Disease Medication Leukemia Refractory Acute Myeloid Leukemia Immune Mediated Diseases Acute Leukemia High Risk Myelodysplastic Syndrome
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 13.86
52 Week Low 5.17
Average Volume 138,115
200-Day Moving Average 9.0308
50-Day Moving Average 6.851
20-Day Moving Average 7.6835
10-Day Moving Average 8.51
Average True Range 0.6193
ADX 27.53
+DI 31.6786
-DI 10.1246
Chandelier Exit (Long, 3 ATRs ) 7.922099999999999
Chandelier Exit (Short, 3 ATRs ) 7.8279
Upper Bollinger Band 9.7893
Lower Bollinger Band 5.5777
Percent B (%b) 0.86
BandWidth 54.813562
MACD Line 0.7274
MACD Signal Line 0.5187
MACD Histogram 0.2087
Fundamentals Value
Market Cap 242.12 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -4.37
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.84
Resistance 3 (R3) 9.90 9.76 9.73
Resistance 2 (R2) 9.76 9.60 9.73 9.70
Resistance 1 (R1) 9.49 9.51 9.42 9.43 9.66
Pivot Point 9.35 9.35 9.32 9.32 9.35
Support 1 (S1) 9.08 9.19 9.01 9.02 8.78
Support 2 (S2) 8.94 9.10 8.91 8.74
Support 3 (S3) 8.67 8.94 8.71
Support 4 (S4) 8.61